Our researchers are proud of the contributions they make, in collaboration with our research center partners, to the field of Life Sciences.

Immunity April 2020

CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

A Teijeira et al.

Current pharmaceutical design March 2020

Focus on the use of Resveratrol as adjuvant in glioblastoma therapy

Dionigi L et al.

Biomedicine & Pharmacotherapy March 2020

Inhibition of osteoclast activity by complement regulation with DF3016A, a novel small-molecular-weight C5aR inhibitor

R D'Angelo et al.

Nature February 2020

Topical recombinant human Nerve growth factor (rh-NGF) is neuroprotective to retinal ganglion cells by targeting secondary degeneration

Guo, L., Davis, B.M., Ravindran, N. et al.

Biomedicine & Pharmacotherapy February 2020

Inhibition of CXCL1-CXCR2 axis ameliorates cisplatin-induced acute kidney injury by mediating inflammatory response

Liu P et al.

Aging January 2020

Autocrine CXCL8-dependent invasiveness triggers modulation of actin cytoskeletal network and cell dynamics

A Antonosante et al.

J Int Soc Sports Nutr. January 2020

Effects of a commercially available branched-chain amino acid-alaninecarbohydrate-based sports supplement on perceived exertion and performance in high intensity endurance cycling tests

M. Gervasi, D. Sisti, S.o Amatori, S. Donati Zeppa, G. Annibalini, G. Piccoli, L. Vallorani, P. Benelli, M. B. L. Rocchi, E. Barbieri, A. R. Calavalle, D. Agostini, C. Fimognari, V. Stocchi, P.Sestili

Ophthalmology January 2020

Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial

SC Pflugfelder et al.

The British journal of ophthalmology January 2020

Effect of Recombinant Human Nerve Growth Factor Eye Drops in Patients With Dry Eye: A Phase IIa, Open Label, Multiple-Dose Study

M Sacchetti et al.

Molecular cancer therapeutics December 2019

Fenretinide, Tocilizumab, and Reparixin Provide Multifaceted Disruption of Oral Squamous Cell Carcinoma Stem Cell Properties: Implications for Tertiary

Mallert SR et al.

Publications per author: 57
Citations: 1699
H-index (2015-2016): 39.5
H-index (2017-2018): 42.4
H-index (2019-2020): 51.5

Number of documents to citations ratio

Source: Elsevier Scopus

Weighted number of publications per thematic area

Source: Elsevier Scopus